ImmuCell Corp (ICCC) stock

ICCCNasdaqIn Vitro & In Vivo Diagnostic SubstancesFiscal year ends December 31

Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 12, 2026Score 12/3016% above fair value

$10.22+0.03 (+0.29%)

Close on Nov 12, 2026Market cap $92.82MP/E 51.1Yield –

ImmuCell enterprise value

Enterprise value is market cap plus debt, minus cash: the value of the whole business to all its investors.

ImmuCell's enterprise value was $91.99M on Nov 11, 2026, against $49.39M a year earlier. Over the last 5 years it ranged from $33.86M to $103.30M, with a median of $54.19M.

Enterprise Value at the end of each year

Period	Period end	Value	Change
2026	Nov 11, 2026	$91.99M	+50.2%
2025	Dec 31, 2025	$61.24M	+16.5%
2024	Dec 31, 2024	$52.58M	+5.7%
2023	Dec 29, 2023	$49.76M	+29.5%
2022	Dec 30, 2022	$38.43M	-25.3%
2021	Dec 31, 2021	$51.44M	+10.0%
2020	Dec 31, 2020	$46.76M	+28.8%
2019	Dec 31, 2019	$36.31M	-20.8%
2018	Dec 31, 2018	$45.85M	+8.9%
2017	Dec 29, 2017	$42.10M	+209.6%
2016	Dec 30, 2016	$13.60M	-21.9%
2015	Dec 31, 2015	$17.40M	+62.1%
2014	Dec 31, 2014	$10.74M	+43.1%
2013	Dec 31, 2013	$7.51M	+1.0%
2012	Dec 31, 2012	$7.43M	-18.2%
2011	Dec 30, 2011	$9.09M	+7.0%
2010	Dec 31, 2010	$8.49M	–